SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Lorraine Hansberry (HR-ML034)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 19judgment calls in the dossier
- 3protocol deviations
- 5orders and referrals without results in the record
- 1evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the borderline resectable staging, the choice and dosing of modified FOLFIRINOX with a dexamethasone-sparing antiemetic plan, the reading of CA 19-9 after biliary drainage, the timing of apixaban after a bleeding duodenal tumor, insulin for diabetes after pancreaticoduodenectomy, and the chemotherapy after surgery without oxaliplatin. |
| provenance review | not_started | | | She died in 1965; the recent-death rule does not apply. Claims rest on the PBS American Masters timeline, two reference encyclopedias, Biography.com and Wikipedia. The primary site of her cancer is recorded as R because the sources disagree; everything clinical is synthetic. |
| safe messaging review | not_started | | | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative, friend or historical physician is given a role in the modern episode, and her private relationships are not used beyond the documented marriage. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. She died in 1965, so the rule does not apply. The claims are still limited to what the fetched sources state. The New York Times obituary, the Library of Congress pages and the Lorraine Hansberry Literary Trust site could not be fetched (blocked or moved), and Imani Perry’s Looking for Lorraine was not read and no reliable quotation of its medical account was found; none of them is cited.
- The site of her cancer (R). Most reference works and Biography.com say pancreatic cancer; the PBS American Masters timeline says cancer of the duodenum; Women in World History says colon cancer that had spread to the pancreas. No pathology was found. The conflict is recorded as R, disputed (CLM-0011), linked to the modern diagnosis but not resolved by it. The modern episode uses a pancreatic head adenocarcinoma invading the duodenum, which fits both the pancreatic and the duodenal accounts and the documented bleeding “ulcers”; this is a teaching choice.
- Date of diagnosis. PBS, the Scribner encyclopedia and Wikipedia put the diagnosis in 1963; Biography.com says 1964. Women in World History dates the first fainting spells and nausea to April 1963. 1963 is preferred because three sources agree and the documented operations of June and August 1963 require it.
- Index age and dates. The synthetic date of birth is May 19, 1993 (shift 63 years). The index visit on April 20, 2026 maps to April 20, 1963, when she was 32, in the month Women in World History gives for the first symptoms and before the collapse and admission. The assignment suggested about 33; 32 was used because she turned 33 only in May 1963, after the documented onset, and an index age of 33 would place the presentation after it. All visits map to April to October 1963, within her lifetime; they are not a claim about where she was. The operation on August 24, 2026 maps to the month of her documented surgery in Boston, which it does not claim to describe.
- Intake claims. The April 1963 onset (CLM-0006) is shown at intake; the collapse, admission and diagnosis (CLM-0007) and the operations (CLM-0008) are linked to a timeline event dated “by June 1963,” because PBS gives no month for the collapse and it preceded the June operation, so they do not appear in the intake documents.
- Disclosure. PBS records that she was told she had anemia and bleeding ulcers while her doctors diagnosed cancer. The record states this as history only and attributes no modern decision to anyone; in the modern episode the diagnosis, stage and aim of treatment are explained to her plainly, at her request, which is the intended contrast.
- Presenting problem. Epigastric pain with weight loss (R10.13) and new hyperglycemia (R73.09) are resolved at the diagnosis visit on May 4, 2026, when pancreatic head adenocarcinoma (C25.0, both_with_link), diabetes due to the cancer (E08.9), exocrine insufficiency (K86.81), cancer pain (G89.3) and bile duct obstruction (K83.1) are recorded. Iron deficiency anemia from blood loss (D50.0) is recorded at intake and stays active. The intake documents state only what was known then.
- Synthetic clinical picture. All visits, results, imaging, pathology, stage (borderline resectable), the regimen and doses (modified FOLFIRINOX for six cycles at a body surface area of 1.58 m2, then six cycles of fluorouracil, leucovorin and irinotecan), the genetic and tumor results (germline negative; KRAS G12D, microsatellite stable), the operation and its pathology (ypT2N1, R0), her height (163 cm) and weights are synthetic. Qualitative results (biopsies, hepatitis and HIV tests, pregnancy test, genetic results, stool C. difficile test) are in note text only.
- Germline result. The germline panel is negative by design: a positive result would imply a health fact about her real blood relatives. The plan states that cascade testing would follow only if a variant were found.
- Fertility. The record has her decline egg or embryo freezing so that chemotherapy is not delayed. This is a synthetic choice for teaching, not a claim about her real wishes about children.
- Private relationships. Her documented marriage is recorded as the sources state it, with the conflict over the year of divorce (1962 or 1964). The Scribner encyclopedia also documents that she wrote to the lesbian periodical The Ladder; it is not used, because it is not needed for this episode’s social history. The modern episode gives no partner, relative or friend a role; her health care agent is unnamed.
- Equity. The teaching objective and the intake plan cite the documented disparities in pancreatic cancer care for Black Americans (later diagnosis, less surgery, longer time to treatment). The urgent care visit that called her pain indigestion and stress is synthetic and is not a claim about her real care.
- Sick visit. Grade 2 irinotecan diarrhea on day 4 of cycle 5 (K52.1), chosen because it is a common, expected effect of her regimen, interacts with her enzyme replacement, diabetes and electrolytes, and insinuates no undocumented real diagnosis. It was treated with fluids, potassium, magnesium and loperamide, and irinotecan was reduced by one dose level.
- Preventive visit. A periodic adult preventive visit at 33 (CPT 99395 and 99497 in plain text) during chemotherapy after surgery: influenza and COVID-19 vaccines between cycles; PCV20 and both recombinant zoster doses already given before and during chemotherapy; cervical screening due and planned after chemotherapy at her choice (recorded as due, since the schema has no deferred status for prevention items); hepatitis B vaccination after chemotherapy; contraception without estrogen; and advance care planning with an unnamed agent.
- Focused visits. The four chronic-care follow-ups (diagnosis and consultation, cycle 4, after six cycles, and six weeks after surgery) are documented as focused visits on the NCCN pancreatic guideline, the ASCO guidance listed above, the ADA Standards and the CMID diabetes and anemia monographs. Synthetic findings introduced: oxaliplatin neuropathy (G62.0) at cycle 4, and acquired partial absence of the pancreas (Z90.411) after surgery. Two protocol deviations are recorded instead of invented results: (1) the dilated eye examination and urine albumin-to-creatinine ratio due when diabetes was diagnosed were not arranged; recorded at cycle 4 and after six cycles, no harm expected, the urine test done after surgery (12 mg/g) and the eye examination the following week (normal, reported at the preventive visit); (2) the interim CT ordered at cycle 4 was never scheduled; no harm, since CA 19-9 kept falling and the CT after six cycles showed a response; corrective action: imaging orders tracked by the nurse navigator.
- Thromboprophylaxis. Her Khorana score was 3, but apixaban was held at diagnosis because the duodenal tumor had bled, and started at cycle 4 after eight weeks without bleeding. This timing is a clinical judgment call for review.
- Consultation. The medical oncology referral and the consultation by Samuel Adeyemi-Rourke, MD (a fictional consultant), on the diagnosis day, are S. The consultant answers the six referral questions in line with what the record shows afterwards: borderline resectable disease; six cycles of modified FOLFIRINOX, then pancreaticoduodenectomy with vein resection (R0), then chemotherapy after surgery; germline and tumor testing; palliative care, enzyme replacement and low-dose opioid; insulin after surgery; apixaban once bleeding settled and enoxaparin after surgery; and fertility counseling. His recommendation of an interim CT after four cycles was not carried out, as the visit after six cycles records.
- Real people. Robert Nemiroff appears only in the claims. No relative, friend, collaborator or historical physician is given a role in the modern episode, and no other figure with a record in the dataset is named.
- Not used. Her father’s first name is given as Charles in Women in World History and as Carl Augustus elsewhere; Carl is used. That source also gives her age at death as 35; she was 34. Accounts that her husband and doctors kept the diagnosis from her (found only on low-quality sites) are not claimed beyond the PBS statement. Her smoking, alcohol use and private papers were not researched.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-06-29 Progress note 03 (C-CDA) | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | A deviation: the dilated eye examination and urine albumin-to-creatinine ratio planned when diabetes was diagnosed were not arranged, amid staging and the start of chemotherapy. Harm is unlikely after two months of mild diabetes, but the check is a standard of care. Corrective action: both booked with the visit after surgery, when treatment visits are fewer |
2026-08-10 Progress note 05 (C-CDA) | Interim restaging CT | Every two months during chemotherapy before surgery | A deviation: the interim CT ordered at cycle 4 was never scheduled. No harm resulted: CA 19-9 kept falling and today's CT shows a response without progression. Corrective action: the nurse navigator now tracks every imaging order to a booked date |
2026-08-10 Progress note 05 (C-CDA) | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Still outstanding (see the deviation at cycle 4); booked with the visit after surgery |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-05-04 Progress note 02 (C-CDA) | Laboratory | Hepatitis B, hepatitis C and HIV screening | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today |
2026-05-04 Progress note 02 (C-CDA) | Laboratory | Germline multigene panel | Ordered | Includes BRCA1, BRCA2, PALB2, ATM, CDKN2A, the Lynch syndrome genes, STK11 and TP53; result in about three weeks |
2026-05-04 Progress note 02 (C-CDA) | Laboratory | Tumor molecular profiling | Ordered | Next-generation sequencing on the EUS cores, with mismatch repair status and fusion testing |
2026-05-04 Progress note 02 (C-CDA) | Referral | Palliative care | Referred | Outpatient palliative care consultation in two days |
2026-06-29 Progress note 03 (C-CDA) | Imaging | Interim restaging CT | Ordered | Ordered today for two weeks from now, before cycle 5 |
Evidence to check
Retrospective claims (R)
| Claim | Statement | Certainty |
|---|
| CLM-0011 | The primary site of her cancer is recorded differently: most reference works give pancreatic cancer; the PBS American Masters timeline gives cancer of the duodenum; and Women in World History describes colon cancer that had spread to the pancreas. One biography dates the diagnosis to 1964 rather than 1963. | disputed |
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-04-20 | Hemoglobin | 9.1 g/dL (low) | Low |
| 2026-04-20 | MCV | 74 fL (low) | Low |
| 2026-04-20 | Ferritin | 6 ng/mL (low) | Low |
| 2026-04-20 | Glucose | 132 mg/dL (high) | High |
| 2026-04-20 | ALT | 48 U/L (high) | High |
| 2026-04-20 | AST | 41 U/L (high) | High |
| 2026-04-20 | Alkaline phosphatase | 236 U/L (high) | High |
| 2026-04-20 | Total bilirubin | 1.6 mg/dL (high) | High |
| 2026-04-20 | Hemoglobin A1c | 6.6% (high) | High |
| 2026-05-04 | Hemoglobin | 10.4 g/dL (low) | Low |
| 2026-05-04 | Glucose | 141 mg/dL (high) | High |
| 2026-05-04 | Alkaline phosphatase | 168 U/L (high) | High |
| 2026-05-04 | CA 19-9 | 486 U/mL (high) | High |
| 2026-05-04 | CEA | 3.9 ng/mL (high) | High |
| 2026-06-29 | Hemoglobin | 11.2 g/dL (low) | Low |
| 2026-06-29 | Glucose | 128 mg/dL (high) | High |
| 2026-06-29 | Alkaline phosphatase | 120 U/L (high) | High |
| 2026-06-29 | CA 19-9 | 210 U/mL (high) | High |
| 2026-07-16 | Hemoglobin | 11 g/dL (low) | Low |
| 2026-07-16 | Sodium | 134 mmol/L (low) | Low |
| 2026-07-16 | Potassium | 3.2 mmol/L (low) | Low |
| 2026-07-16 | Glucose | 118 mg/dL (high) | High |
| 2026-07-16 | Magnesium | 1.6 mg/dL (low) | Low |
| 2026-08-10 | Hemoglobin | 10.9 g/dL (low) | Low |
| 2026-08-10 | Glucose | 124 mg/dL (high) | High |
| 2026-08-10 | Hemoglobin A1c | 7% (high) | High |
| 2026-08-10 | CA 19-9 | 41 U/mL (high) | High |
| 2026-10-05 | Hemoglobin | 10.6 g/dL (low) | Low |
| 2026-10-05 | Glucose | 156 mg/dL (high) | High |
| 2026-10-05 | Alkaline phosphatase | 110 U/L (high) | High |
| 2026-10-05 | Albumin | 3.4 g/dL (low) | Low |